**Celebrating GSK’s Expanded Vaccine & Infectious Disease R&D Facility in Cambridge, Massachusetts**

GSK Expands U.S. R&D Footprint in Massachusetts, Signaling Commitment to Innovation and Job Growth

Cambridge, MA – December 5, 2025 – GSK (GlaxoSmithKline) today celebrated the official opening of its expanded research and development (R&D) facility in Cambridge, Massachusetts, marking a significant investment in U.S. innovation and a growing presence within the state’s thriving biopharmaceutical sector. The new space serves as the U.S. headquarters for GSK’s Vaccine & Infectious Disease R&D efforts.

The expansion reflects GSK’s substantial growth in Massachusetts since 2019, increasing from a single site to four across the Commonwealth. The company now ranks among the largest biopharma employers in the state, demonstrating a strong commitment to both the local community and its workforce.

“Massachusetts is a true hub of innovation for us,” stated a GSK representative during the ribbon-cutting ceremony, which was attended by local government and public health officials, including a virtual appearance by Massachusetts Governor Maura Healey. Governor Healey’s office has been a vocal advocate for pro-innovation policies within the state, fostering an environment conducive to growth for companies like GSK.

The newly expanded facility will house teams dedicated to cutting-edge research and development, focusing on vaccines and infectious disease solutions. GSK emphasized the importance of collaboration across all its divisions – from R&D and manufacturing to sales and marketing – united by a shared passion for scientific advancement and patient access.

The opening was also an prospect to recognize the contributions of key individuals instrumental in the expansion’s success, including Mother Dhillon, Christine Donahue, Sandra Catherine Ribeiro, Chris Bryce, and Pei-Yong Shi. Robert Goldstein,Commissioner of the Massachusetts Department of Public Health,and Denise Simmons,Mayor of the City of Cambridge,were also acknowledged for their support.

This expansion underscores GSK’s dedication to addressing global health challenges through innovative science and reinforces Massachusetts’ position as a leading center for biopharmaceutical research and development. The company’s continued investment promises further job creation and economic benefits for the region.

What specific technologies within the expanded facility are expected to accelerate the identification of vaccine candidates?

A Hub for Cutting-Edge Biotechnology & Pharmaceutical Innovation

GlaxoSmithKline (GSK) has considerably expanded its research and advancement (R&D) footprint in Cambridge,Massachusetts,solidifying its commitment to combating infectious diseases and pioneering next-generation vaccines. This expansion isn’t just about bricks and mortar; it represents a substantial investment in scientific talent, advanced technologies, and collaborative research – all crucial elements in the fight against global health threats. The Cambridge facility is now a cornerstone of GSK’s global R&D network, focusing on areas like immunology, vaccine development, and novel therapeutics.

Key Features of the Expanded Facility

the expanded Cambridge R&D facility boasts state-of-the-art laboratories and collaborative workspaces designed to accelerate scientific revelation. Here’s a breakdown of key features:

* Advanced Laboratories: Equipped with cutting-edge instrumentation for genomics, proteomics, and high-throughput screening. This allows for faster and more efficient identification of potential vaccine candidates and therapeutic targets.

* Collaboration Spaces: Designed to foster interdisciplinary collaboration between GSK scientists and external partners, including academic institutions and biotech companies in the Boston/Cambridge area.

* Expanded Vaccine Development Capabilities: Increased capacity for preclinical and clinical development of vaccines targeting a wide range of infectious diseases, including respiratory syncytial virus (RSV), influenza, and emerging pathogens.

* Focus on mRNA Technology: A important portion of the expansion is dedicated to advancing GSK’s mRNA vaccine platform, a technology proven effective during the COVID-19 pandemic.

* Digital Innovation Hub: Integration of data science, artificial intelligence (AI), and machine learning (ML) to accelerate drug discovery and improve clinical trial design.

Impact on Vaccine Development & Infectious Disease Research

GSK’s investment in Cambridge directly impacts several critical areas of vaccine and infectious disease research:

* RSV Vaccine Development: The facility plays a pivotal role in the development and testing of GSK’s Arexvy, the first RSV vaccine approved for older adults in the US. Further research aims to expand RSV vaccine protection to other vulnerable populations.

* Influenza vaccine Innovation: cambridge-based scientists are working on next-generation influenza vaccines, including those offering broader protection against multiple strains and longer-lasting immunity.

* Pandemic Preparedness: The expanded facility strengthens GSK’s ability to rapidly respond to emerging infectious disease threats and develop vaccines and therapeutics to combat future pandemics. This includes research into novel antiviral therapies and platform technologies for rapid vaccine development.

* Shingles Vaccine Research: Ongoing research into improving Shingrix, GSK’s highly effective shingles vaccine, is also conducted at the Cambridge site.

* HIV Research: GSK is actively involved in HIV vaccine research, and the Cambridge facility contributes to these efforts through immunological studies and the development of novel vaccine candidates.

The Cambridge Biotech Ecosystem & GSK’s Role

Cambridge, Massachusetts, is a global hub for biotechnology and pharmaceutical innovation.GSK’s expanded presence contributes to and benefits from this vibrant ecosystem.

* Proximity to Leading Universities: The facility is located near harvard University and MIT, providing access to a highly skilled workforce and opportunities for collaborative research.

* Collaboration with Biotech Companies: GSK actively partners with numerous biotech companies in the Cambridge area, fostering innovation and accelerating drug development.

* Talent Acquisition: The expansion allows GSK to attract and retain top scientific talent, further strengthening its R&D capabilities.

* Economic Impact: GSK’s investment creates jobs and stimulates economic growth in the Cambridge area.

GSK’s Commitment to Innovation: A Timeline of Key Developments

GSK’s commitment to vaccine and infectious disease research has been demonstrated through a series of strategic investments and partnerships:

* 2008: GSK establishes a significant R&D presence in Cambridge, Massachusetts.

* 2017: GSK invests in a new R&D facility focused on immunology and vaccine development.

* 2021: GSK announces a major expansion of its Cambridge R&D facility, driven by the success of its Shingrix and RSV vaccine programs.

* 2023: GSK’s Arexvy RSV vaccine receives FDA approval, marking a significant milestone in the fight against RSV.

* 2025: Completion of the latest expansion, further solidifying GSK’s commitment to Cambridge and its role in global health innovation.

Benefits of GSK’s Investment for Public Health

The expansion of GSK’s Cambridge R&D facility offers significant benefits for public health globally:

* Faster Vaccine Development: Accelerated research and development timelines for new vaccines targeting critical infectious diseases.

* Improved Vaccine Efficacy: Development of vaccines offering broader protection and longer-lasting immunity.

* Enhanced Pandemic Preparedness: Increased capacity to respond rapidly to emerging infectious disease threats.

* **Access to